2-54 Strategic review 55-86 Financial review & risk 87-136 Governance & remuneration 137-223 Financial statements 224-248 Investor information GSK Annual Report 2012 239 Shareholder information We have not acquired or disposed of any interests in our own shares Share capital and control during the period under review, other than in connection with our Details of our issued share capital and the number of shares held share buy-back programme.
in Treasury as at 31 December 2012 can be found in Note 33 to Share buy-back programme the financial statements, Share capital and share premium account.
The Board has been authorised to issue and allot Ordinary Shares Our shares are listed on the London Stock Exchange and are also under Article 9 of the companys Articles of Association.
The power quoted on the New York Stock Exchange NYSE in the form of under Article 9 and the authority for the company to make American Depositary Shares ADS.
Each ADS represents two purchases of its own shares are subject to shareholder authorities Ordinary Shares.
For details of listed debt and where it is listed which are sought on an annual basis at our Annual General Meeting refer to Note 32 to the financial statements, Net debt.
Any shares purchased by the company may be cancelled or Holders of Ordinary Shares are entitled to receive dividends, when held as Treasury shares.
declared, the companys Annual Report, to attend and speak During 2012, we continued our long-term share buy-back at general meetings of the company, to appoint proxies and to programme and 174 million shares were purchased at a total cost exercise voting rights.
No shares were purchased in the period 1 January There are no restrictions on the transfer, or limitations on the to 28 February 2013. holding, of Ordinary Shares and no requirements to obtain approval Our programme covers purchases of shares for cancellation or prior to any transfers.
No Ordinary Shares carry any special rights to be held as Treasury shares, in accordance with the authority with regard to control of the company and there are no restrictions renewed by shareholders at the AGM in May 2012, when the on voting rights.
Major shareholders have the same voting rights company was authorised to purchase a maximum of just under per share as all other shareholders.
Details of shares purchased, expectations of There are no known arrangements under which financial rights are future repurchases, those cancelled, and those held as Treasury held by a person other than the holder of the shares and no known shares are disclosed in Note 33 to the financial statements Share agreements on restrictions on share transfers or on voting rights.
capital and share premium account.
Shares acquired through our share schemes and plans rank equally The exact amount and timing of any future purchases, and the with the other shares in issue and have no special rights.
The extent to which repurchased shares will be held as Treasury shares trustees of our Employee Share Ownership Plan trusts have waived rather than being cancelled, will be determined by the company their rights to dividends on shares held by those trusts.
and is dependent on market conditions and other factors.
Exchange controls and other limitations affecting Market capitalisation security holders The market capitalisation, based on shares in issue excluding Other than certain economic sanctions which may be in force from Treasury shares, of GSK at 31 December 2012 was 65.47 billion.
time to time, there are currently no applicable laws, decrees or At that date, GSK was the fifth largest company by market regulations restricting the import or export of capital or affecting capitalisation in the FTSE index.
the remittance of dividends or other payments to holders of the companys shares who are non-residents of the UK.
Similarly, other Share price than certain economic sanctions which may be in force from time 2012 2011 2010 to time, there are no limitations relating only to non-residents of the UK under English law or the companys Articles of Association At 1 January 14.72 12.40 13.20 on the right to be a holder of, and to vote in respect of, the At 31 December 13.35 14.72 12.40 companys shares.
Decrease increase 9.3% 18.7% 6.1% High during the year 15.08 14.74 13.40 Interests in voting rights Low during the year 13.18 11.28 10.95 Other than as stated below, as far as we are aware, there are no persons with significant direct or indirect holdings in the company.
The table above sets out the middle market closing prices.
The Information provided to the company pursuant to the Financial companys share price decreased by 9.3% in 2012.
This compares Services Authoritys FSA Disclosure and Transparency Rules DTRs with an increase in the FTSE 100 index of 5.8% during the year.
is published on a Regulatory Information Service and on the The share price on 28 February 2013 was 14.56. companys website.
At 28 February 2013, the company had received notications in UK US$ accordance with the FSAs DTRs of the following notiable interests 15 60 in the voting rights in the companys issued share capital: 14 55 13 50 Percentage of No.
of issued 12 45 shares capital % 11 40 BlackRock, Inc. 271,061,000 5.52 Legal & General Group Plc 153,140,293 3.12 10 35 9 30 Percentage of Ordinary Shares in issue, excluding Treasury shares.
8 25 BNY Mellon Depositary Receipts is the Depositary for the companys 01 01 10 31 12 10 31 12 11 31 12 12 ADS, which are listed on the NYSE.
Ordinary Shares representing the companys ADR programme, which is managed by the Depositary, UK share price UK US ADS price US$ are registered in the name of BNY Nominees Limited.
Details of the number of Ordinary Shares held by the Depositary can be found on page 244.
